Healius Limited (HLS.AX)
- Previous Close
1.2100 - Open
1.2000 - Bid 1.2000 x 676100
- Ask 1.2150 x 1520800
- Day's Range
1.1900 - 1.2200 - 52 Week Range
1.0900 - 3.0220 - Volume
2,546,219 - Avg. Volume
2,704,939 - Market Cap (intraday)
874.95M - Beta (5Y Monthly) 0.65
- PE Ratio (TTM)
-- - EPS (TTM)
-1.6500 - Earnings Date Feb 27, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 7, 2022
- 1y Target Est
1.25
Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through three segments: Pathology, Imaging, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services. It also provides cataract surgery, colonoscopy, gastroscopy, plastic and cosmetic surgery, skin cancer removal, IVF egg collection, and gynaecological surgery services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetpath Laboratory, Vetnostics, QML Vetnostics, TML Vetnostics, ASAP Laboratory, Abbott Pathology, TML Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs; Lumus Imaging; and Montserrat brands. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius Limited was incorporated in 1994 and is based in Sydney, Australia.
www.healius.com.au10,500
Full Time Employees
June 30
Fiscal Year Ends
Sector
Industry
Recent News: HLS.AX
Performance Overview: HLS.AX
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HLS.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HLS.AX
Valuation Measures
Market Cap
874.95M
Enterprise Value
2.40B
Trailing P/E
--
Forward P/E
20.92
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.43
Price/Book (mrq)
0.83
Enterprise Value/Revenue
1.42
Enterprise Value/EBITDA
-3.54
Financial Highlights
Profitability and Income Statement
Profit Margin
-57.63%
Return on Assets (ttm)
1.31%
Return on Equity (ttm)
-68.02%
Revenue (ttm)
1.69B
Net Income Avi to Common (ttm)
-984.1M
Diluted EPS (ttm)
-1.6500
Balance Sheet and Cash Flow
Total Cash (mrq)
85.7M
Total Debt/Equity (mrq)
153.80%
Levered Free Cash Flow (ttm)
293.38M
Research Analysis: HLS.AX
Analyst Price Targets
Fair Value
No Fair Value available for this ticker